Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives

被引:0
作者
T. Mocan
Z. Sparchez
R. Craciun
C. N. Bora
D. C. Leucuta
机构
[1] “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca,3rd Medical Department
[2] Institute for Gastroenterology and Hepatology,Medical Informatics and Biostatistics Department
[3] “Iuliu Hatieganu” University of Medicine and Pharmacy,undefined
来源
Clinical and Translational Oncology | 2019年 / 21卷
关键词
Hepatocellular carcinoma; Immunotherapy; Checkpoint inhibitors; Programmed cell death protein-1; Ligand programmed death-ligand-1;
D O I
暂无
中图分类号
学科分类号
摘要
Hepatocellular carcinoma (HCC) is the most common primary neoplasia of the liver. There have been tremendous efforts in the development of therapeutic strategies in the last decades. As opposed to other cancer entities immunotherapy has just recently gained popularity in HCC. Among various immunotherapy approaches, programmed cell death protein-1 (PD-1), and its ligand programmed death receptor ligand-1 (PD-L1) axis became one of the most promising pathway of the decade. The scientific interest in PD-1/PD-L1 axis is definitely justified due to: ability to detect PD-L1 expression in patients that underwent resection for HCC with prognostic values; the role of serum PD-L1 as a tool to identify early recurrences and to monitor treatment outcome; PD-1/PDL1 is a highly targetable pathway, with possible predictive markers, and with high clinical applicability that might help us in selecting a subgroup of HCC patients who are most likely to benefit from PD-1/PD-L1 inhibitors. In this review we will first discuss the prognostic role of PD-1/PD-L1 as a bio-marker in various clinical scenarios. Afterwards we will critically analyse the recently published trials with PD-1/PD-L1 inhibitors in HCC either alone or in combination with other treatment modalities. The higher focus will be on clinical rather than preclinical studies. Nevertheless, the strengths and limits of PD-1/PD-L1 axis in both prognosis and therapy of HCC will be highlighted.
引用
收藏
页码:702 / 712
页数:10
相关论文
共 289 条
  • [1] Ferlay J(2015)Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 Int J Cancer 136 359-386
  • [2] Soerjomataram II(2018)EASL clinical practice guidelines: management of hepatocellular carcinoma J Hepatol 69 182-236
  • [3] Dikshit R(2009)Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 15 971-979
  • [4] Eser S(2016)Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial World J Hepatol. 8 957-960
  • [5] Mathers C(2015)Immune checkpoint blockade: a common denominator approach to cancer therapy Cancer Cell 27 450-461
  • [6] Rebelo M(2014)Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions Hepatology 60 1776-1782
  • [7] Gao Q(2009)Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model Int J Hyperth 25 374-382
  • [8] Wang XY(2010)Antigen-presenting cell function in the tolerogenic liver environment Nat Rev Immunol 10 753-766
  • [9] Qiu SJ(2012)The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 252-264
  • [10] Yamato I(2017)Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Lancet 389 2492-2502